NATAP/EASL: BMS NS5A+GS7977 IFN-Free 100% SVR GT1-here is the data

[Guest guest]

Subject: NATAP/EASL: BMS NS5A+GS7977 IFN-Free 100% SVR GT1-here is the data

Potent Viral Suppression With

the All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977

(Nucleotide NS5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With

Chronic HCV GT1, 2, or 3 - see attached full poster report

Reported by Jules LevinEASL 2012 Barcelona,

Spain April 18-22Sulkowski et al

CONCLUSIONS This represents the first report of the safety and efficacy of an NS5A replication complex inhibitor combined with a nucleotide NS5B polymerase inhibitor as therapy for HCV infection  Overall, the all oral, interferon-free regimen DCV + GS-7977 with or without ribavirin for 24 weeks cured > 95% of GT1, 2, and 3 infected treatment naive patients, including 100% of all GT1 patients treated  The all oral, once daily, interferon-free, ribavirin-free regimen of DCV + GS-7977 cured 100% of GT1 and > 90% of 2 & 3 infected treatment naive patients  DCV + GS-7977 achieved SVR independent of IL28B genotype or HCV subtype  Ribavirin contributed adverse effects but had no effect on virologic response  DCV + GS-7977 was generally well tolerated, based on the available interim 12 week on-treatment data  DCV + GS-7977 may represent a significant advance in the treatment of HCV; further research is needed to confirm these findings

2 of 2 Photo(s)

Screen shot 2012-04-19 at 6.12.20 AM.png

1 of 1 File(s)

Potent Viral Suppression With the All.docx